epiClinicalA fictional CRO

epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.

EPI-620, Phase III. In planning

Chronic obstructive pulmonary disease with frequent exacerbations

LWR-620 against placebo to reduce exacerbations in COPD. Sponsor: Litware Respiratory (fictional), Respiratory.

The QTLs this study should set before its first patient, in priority order. Their charts start once patients are randomised.

RankQTLLikelihoodImpactWhy it is likely hereWatched at sites byWarningLimitCritical
1Stopped study treatment earlyEvidence grade B32
  • Placebo or no-added-treatment control arm (PD-05)From the design: What does the control arm receive? Placebo or no added treatment
12.5%15%22%
2Ineligible patients randomisedEvidence grade B22
  • Comorbidity exclusions (PD-15)From the design: Does the protocol exclude common comorbidities? Yes
  • Restrictive eligibility criteria and protocol complexity (EB-04)From the design: How many non-essential exclusions does the protocol carry? One or two
  • Eligibility criteria exclude patients (comorbidity, age, performance status, language) (PB-02)From the design: How many non-essential exclusions does the protocol carry? One or two; Does the protocol exclude common comorbidities? Yes
  • Restrictive eligibility criteria (organ function, brain metastases, prior or concurrent malignancy, HIV, laboratory thresholds, performance status) (PD-01)From the design: How many non-essential exclusions does the protocol carry? One or two
  • Number of eligibility criteria and complexity growth (PD-02)From the design: How many non-essential exclusions does the protocol carry? One or two
4%5%14.5%
3Missing primary endpoint dataEvidence grade A13None of its drivers applies to this design10.1%15%33.2%
4Lost to follow-up or withdrew consentEvidence grade A13None of its drivers applies to this design4.5%6%24.3%

Critical lines assume each study was designed for 80% power at a two-sided 5% level, and mark where power would fall to 70%. Missing outcome data can bias a result well before it costs power, so its limit, not its critical line, is the one to act on.